TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19768381

Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin, 400 mg once daily for 7-21 days
Number of subjects: 804

Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate, 1,000 mg/200 mg three times daily followed by oral amoxicillin/clavulanate, 500 mg/125 mg three times daily for 7-21 days
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin
Number of subjects: 804

Group type: COMPARATOR
Intervention: Intravenous amoxicillin/clavulanate followed by oral amoxicillin/clavulanate
Number of subjects: 804
Study: 17074784

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study: 15322749

Group type: EXPERIMENTAL
Intervention: Ramipril (15 mg/day)
Number of subjects: 5269

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 5269

Group type: COMPARATOR
Intervention: Placebo (for both ramipril and rosiglitazone)
Number of subjects: 5269
Study: 11567764

Group type: EXPERIMENTAL
Intervention: PncD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PncT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both PncD and PncT
Number of subjects: 50
Study: 9692107

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids treatment for 3 years
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 2147
Study: 7843022

Group type: EXPERIMENTAL
Intervention: Application of a transparent keratoscope during microsurgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No application of a transparent keratoscope during microsurgery
Number of subjects: 0
Study: 2848902

Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines (serotypes 1, 2, or 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines (serotype 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human-rhesus reassortant rotavirus vaccines
Number of subjects: 0
Study: 31835278

Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence derived from real‐time claims data
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence and pharmacist may contact patients by default
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Notification of patient nonadherence and pharmacist may contact patients by physician choice
Number of subjects: 2602

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2602
Study: 31553979

Group type: EXPERIMENTAL
Intervention: Affected ears of MD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contralateral ears of MD patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control ears
Number of subjects: 30
Study: 29075019

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25561079

Group type: EXPERIMENTAL
Intervention: 1-hour therapeutic play intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 95
Study: 23685998

Group type: EXPERIMENTAL
Intervention: Pentacam densitometry measurements in MPS patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pentacam densitometry measurements in control subjects
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Corneal centre density values in MPS patients
Number of subjects: 65
Study: 21145807

Group type: EXPERIMENTAL
Intervention: 400 mg ribavirin/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 800 mg ribavirin/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin treatment
Number of subjects: 71
Study: 19026407

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16739539

Group type: EXPERIMENTAL
Intervention: Predictive model based on age, race, and risk of IPV
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Predictive model applied to validation dataset
Number of subjects: 305
Study: 15215811

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg)
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3408
Study: 11294376

Group type: EXPERIMENTAL
Intervention: Feedback on prescribing rates and problem-oriented educational outreach visits
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 9292674

Group type: EXPERIMENTAL
Intervention: Subconjunctival cefuroxime not administered (n=9)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (n=90)
Number of subjects: 99
Study: 8278160

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study: 3111689

Group type: EXPERIMENTAL
Intervention: Elantan Long (50 mg IS 5‐MN) daily for 12 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 38
Study: 28608523

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 50
Study: 27821027

Group type: EXPERIMENTAL
Intervention: Weekly intralesional triamcinolone injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biweekly intralesional triamcinolone injections
Number of subjects: 0
Study: 24292559

Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery (I-IMR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 22327761

Group type: EXPERIMENTAL
Intervention: Xylitol (chewing gum for mothers and chewable tablets for children, 3 times a day for 3 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Xylitol (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoride varnish (control group)
Number of subjects: 60
Study: 20162736

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nebivolol 20 mg
Number of subjects: 811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nebivolol 5-20 mg
Number of subjects: 811
Study: 18176735

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport; 1000 mouse units (MU) divided between elbow, wrist and finger flexors)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15660663

Group type: EXPERIMENTAL
Intervention: MOG gene polymorphisms (CA)n, (TAAA)n, C1334T, C10991T
Number of subjects: 111

Group type: COMPARATOR
Intervention: Case-control analysis with healthy controls
Number of subjects: 111
Study: 12550145

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 98
Study: 12523328

Group type: COMPARATOR
Intervention: 1 g rectal paracetamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg x kg(‐1) rectal paracetamol
Number of subjects: 24
Study: 9798808

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g
Number of subjects: 14
Study: 7900626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.0 mg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (open-label phase)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (AF group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.0 mg/kg (AF group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (AF group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sotalol 1.5 mg/kg (open-label phase, AF group)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Adverse events (hypotension and dyspnea)
Number of subjects: 93
Study: 2527133

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) and once daily, bedtime extended‐acting insulin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (NovoPen)
Number of subjects: 16
Study: 781234

Group type: EXPERIMENTAL
Intervention: Fenoprofen, 200 to 600 mg every six hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin, 325 to 975 mg every six hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoprofen (long-term use)
Number of subjects: 0
Study: 31647605

Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (0.03, 0.1, 0.3, 1, or 3 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Subcutaneous iscalimab (3 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (10 or 30 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab (3 mg/kg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous iscalimab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 29800080

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (weekly lifestyle counseling and meal replacement diet)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 28496044

Group type: EXPERIMENTAL
Intervention: Gadodiamide (0.1 mol/kg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gadopentetate (0.1 mol/kg)
Number of subjects: 102
Study: 26044516

Group type: EXPERIMENTAL
Intervention: Probiotic group (2 g of powder containing 5 × 10^9 cfu of L. curvatus HY7601 and 5 × 10^9 cfu of L. plantarum KY1032 daily)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 92
Study: 23518872

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602
Study: 21681125

Group type: EXPERIMENTAL
Intervention: Polyurethane dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aquacel dressing
Number of subjects: 50
Study: 19029129

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 767
Study: 16960523

Group type: EXPERIMENTAL
Intervention: 750 mg of soybean‐derived phosphatidylserine (S‐PtdSer), administered daily for 7 days prior to exercise and for 2 days following exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose polymer placebo
Number of subjects: 8
Study: 15331032

Group type: EXPERIMENTAL
Intervention: Simulated walking using a proprietary step-exercise device
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Conventional flying mode (depressing a keyboard key for continuous forward motion)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Passive observation of walking participants
Number of subjects: 4

Group type: COMPARATOR
Intervention: Passive observation of flying participants
Number of subjects: 4
Study: 10674516

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no general anesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (Ropivacaine 0.75%, Ropivacaine 1%, Mepivacaine 2%)
Number of subjects: 60
Study: 9059093

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC‐h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane (1.5 MAC‐h)
Number of subjects: 50
Study: 8103359

Group type: EXPERIMENTAL
Intervention: Fibrin adhesive glue
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no fibrin adhesive)
Number of subjects: 68
Study: 29652792

Group type: EXPERIMENTAL
Intervention: Blue mussel diet (75 g blue mussels, five days a week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control diet (75 g meat, five days a week)
Number of subjects: 39
Study: 27256357

Group type: EXPERIMENTAL
Intervention: ebselen (3600 mg over 24 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 25518523

Group type: EXPERIMENTAL
Intervention: L-carnitine (Elkar, PikFarma)
Number of subjects: 0
Study: 22858387

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 times/week for 4 months)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day for 4 months)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 21184675

Group type: EXPERIMENTAL
Intervention: TPN with daily glutamine supplement of 0.35 g/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenated TPN (Control)
Number of subjects: 43
Study: 18702333

Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha/RBV treatment (n = 18 with 2a, n = 9 with 2b)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: peg‐IFN‐alpha/RBV treatment
Number of subjects: 47
Study: 15912895

Group type: EXPERIMENTAL
Intervention: Minimally invasive SaphLITE harvest
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional saphenous vein harvest
Number of subjects: 200
Study: 12733733

Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg/day plus calcium carbonate (600 mg daily)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Simple vitamin D (ergocalciferol, 30,000 IU weekly) plus calcium carbonate (600 mg daily)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Calcitriol, 0.5 to 0.75 microg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 195
Study: 10100105

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once a day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg once a day)
Number of subjects: 96
Study: 8626362

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 3500
Study: 1725545

Group type: EXPERIMENTAL
Intervention: Diltiazem controlled-release (CR) 120 mg b.i.d.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 56
Study: 6401458

Group type: EXPERIMENTAL
Intervention: Concurrent hormone treatment and cytotoxic chemotherapy
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Sequential hormone treatment and cytotoxic chemotherapy
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Sequential hormone treatment for postmenopausal women in the low-risk category
Number of subjects: 464
Study: 31640763

Group type: EXPERIMENTAL
Intervention: Retention of level IIb
Number of subjects: 522

Group type: COMPARATOR
Intervention: Dissection of level IIb
Number of subjects: 522
Study: 29438073

Group type: EXPERIMENTAL
Intervention: 4-week stroke self-management program
Number of subjects: 128

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 128
Study: 26897450

Group type: COMPARATOR
Intervention: Standard treatment (ST) for anxiety alleviation with anxiolytics
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Compact Disk Recording of Guided Imagery (CDRGI) with ST
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Acupuncture with ST
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Individual guided imagery with ST
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Reflexology with ST
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Individual guided imagery combined with reflexology with ST
Number of subjects: 360
Study: 24814272

Group type: EXPERIMENTAL
Intervention: Autologous periorbital fat injections
Number of subjects: 70
Study: 22553292

Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mn-DPDP
Number of subjects: 15
Study: 19730254

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (5 and 15 cm H2O)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control patients under invasive ventilation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 16
Study: 17088020

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: QST measures
Number of subjects: 20
Study: 16323322

Group type: EXPERIMENTAL
Intervention: Step-wise intervention plan including nutritional counseling (+/‐ lactase and/or psyllium), calcium carbonate, and loperamide.
Number of subjects: 18
Study: 12083630

Group type: EXPERIMENTAL
Intervention: Video intervention group (VG); 15 min video
Number of subjects: 251

Group type: COMPARATOR
Intervention: Non-video comparison group (NVG); no video
Number of subjects: 251
Study: 9523538

Group type: EXPERIMENTAL
Intervention: Leg-O-Meter
Number of subjects: 39
Study: 7664861

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms) and sodium cromoglycate (20 mg) combined
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2708725

Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation and dietary manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 935836

Group type: EXPERIMENTAL
Intervention: Physical training for 4-6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo tablets for 4-6 months (Control group)
Number of subjects: 23
Study: 29863450

Group type: EXPERIMENTAL
Intervention: Home-based pelvic floor muscle exercise (PFME) program supplemented with three supervised physiotherapy sessions.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Home-based PFME program supplemented with three supervised physiotherapy sessions.
Number of subjects: 86
Study: 30898689

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenge
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self-reported food allergy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Symptoms of food allergy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Causative foods
Number of subjects: 55
Study: 28231371

Group type: EXPERIMENTAL
Intervention: Intralipid 10%
Number of subjects: 31

Group type: COMPARATOR
Intervention: ABD (1mg/kg/day in dextrose 5%)
Number of subjects: 31
Study: 27155451

Group type: EXPERIMENTAL
Intervention: Competitive Memory Training (COMET)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) followed by Competitive Memory Training (COMET)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Competitive Memory Training (COMET) followed by Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Self-esteem improvements
Number of subjects: 47
Study: 24164087

Group type: EXPERIMENTAL
Intervention: Pre-operative nebulised budesonide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study: 22998340

Group type: EXPERIMENTAL
Intervention: Sugar-free, artificially sweetened beverage (250 ml per day)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Sugar-containing beverage (250 ml per day providing 104 kcal)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Sugar-free group
Number of subjects: 641

Group type: COMPARATOR
Intervention: Sugar group
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Combined measurements of 136 children who discontinued and 477 who completed the study
Number of subjects: 641
Study: 20634176

Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/d)
Number of subjects: 216
Study: 18250617

Group type: EXPERIMENTAL
Intervention: Ghrelin administration (1 microg/kg)
Number of subjects: 21
Study: 16371523

Group type: EXPERIMENTAL
Intervention: Peripheral Cutting Balloon (PCB)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 340
Study: 11871738

Group type: COMPARATOR
Intervention: Standard amino acid solution (Vintène) for 10 days (Control group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Individualized amino acid solution during the last 5 days (Experimental group)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both groups received total parenteral nutrition for 10 days
Number of subjects: 13
Study: 10502210

Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg daily (E40)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enalapril 10 mg daily (E10)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily (E20)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enalapril 5 mg daily (E10)
Number of subjects: 45
Study: 8524557

Group type: EXPERIMENTAL
Intervention: Group S using Summit ExciMed UV 200
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group V using VisX 20:20 excimer laser system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soft lens fitting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeat PRK
Number of subjects: 20
Study: 1702476

Group type: EXPERIMENTAL
Intervention: Single fraction radiation treatment (8, 10, 12, 15Gy)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Multifraction dose schedule (5Gy x 4, 5Gy x 5, 5Gy x 6)
Number of subjects: 31
Study: 7374197

Group type: COMPARATOR
Intervention: Standard flow delivered by a roller pump
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pulsatile flow induced by a 'pulsatile assist device'
Number of subjects: 10
Study: 31974063

Group type: EXPERIMENTAL
Intervention: Simple supervised exercises (walking and rising from a chair, ∼20 minutes/day)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 268
Study: 30909539

Group type: EXPERIMENTAL
Intervention: HRV-biofeedback training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 50